The global biosimilars market is driven by less expensive alternatives made possible by the major biologics' patents expiring. The demand for reasonably ...

Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...